UNITY Biotechnology (UBX) Provides Pipeline and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
UNITY Biotechnology Provides Pipeline and Business Updates
February 25, 2020 6:00 AM ESTPhase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment
Topline 12- and 24-week results now expected in 2H 2020
First patient dosed in phase 1b study to explore higher dose and repeat doses
First-in-human study initiation for ophthalmology program expected in 2H 2020
SAN FRANCISCO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today provided... More
